|
gptkbp:instanceOf
|
peptide
immunosuppressant drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
1983
|
|
gptkbp:ATCCode
|
L04AD01
|
|
gptkbp:bioavailability
|
30% (oral)
|
|
gptkbp:CASNumber
|
59865-13-3
|
|
gptkbp:contraindication
|
uncontrolled hypertension
malignancy
|
|
gptkbp:discoveredBy
|
gptkb:Jean-François_Borel
|
|
gptkbp:discoveredIn
|
1971
|
|
gptkbp:drugInteraction
|
gptkb:milk
gptkb:phenytoin
gptkb:rifampin
gptkb:NSAIDs
gptkb:erythromycin
gptkb:ketoconazole
|
|
gptkbp:eliminationHalfLife
|
8.4 hours
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:firstIsolatedFrom
|
soil fungus
|
|
gptkbp:hasMolecularFormula
|
C62H111N11O12
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cyclosporine
|
|
gptkbp:KEGGID
|
D00137
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Gengraf
gptkb:Sandimmune
gptkb:Neoral
|
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
|
gptkbp:MeSH_ID
|
D003562
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
1202.61 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Tolypocladium_inflatum
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
4447442
5284373
DB00091
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
hypertension
tremor
nephrotoxicity
hirsutism
gingival hyperplasia
|
|
gptkbp:UNII
|
83HN0GTJ6D
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of psoriasis
treatment of rheumatoid arthritis
|
|
gptkbp:bfsParent
|
gptkb:Erythromycin
gptkb:CYP3_family
gptkb:CYP3A4
gptkb:Lipitor
gptkb:Vytorin
gptkb:Neoral
|
|
gptkbp:bfsLayer
|
5
|